Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

Oliver Sartor, MD
Published: Wednesday, Aug 09, 2017



Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.

Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
 


Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.

Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x